Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Open Label Study to Assess the Efficacy and Safety of Subcutaneous 15mg AKB-9778 Administered Twice Daily for 84 Days in Subjects With Retinal Vein Occlusion

NCT02387788 is registered in ClinicalTrials.gov with Aerpio Therapeutics as lead sponsor.

NCT NCT02387788
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02387788 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Open Label Study to Assess the Efficacy and Safety of Subcutaneous 15mg AKB-9778 Administered Twice Daily for 84 Days in Subjects With Retinal Vein Occlusion
Lead sponsor
Aerpio Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2015
Completion date
April 30, 2017
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinal vein occlusion